ExpreS2ion Biotech Holding AB
STO:EXPRS2
ExpreS2ion Biotech Holding AB
Other
ExpreS2ion Biotech Holding AB
Other Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Other | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
E
|
ExpreS2ion Biotech Holding AB
STO:EXPRS2
|
Other
-kr474k
|
CAGR 3-Years
66%
|
CAGR 5-Years
10%
|
CAGR 10-Years
N/A
|
|
|
Biogaia AB
STO:BIOG B
|
Other
kr0
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Bonesupport Holding AB
STO:BONEX
|
Other
-kr173k
|
CAGR 3-Years
N/A
|
CAGR 5-Years
60%
|
CAGR 10-Years
N/A
|
|
|
Vitrolife AB
STO:VITR
|
Other
-kr10m
|
CAGR 3-Years
6%
|
CAGR 5-Years
2%
|
CAGR 10-Years
N/A
|
|
|
Swedish Orphan Biovitrum AB (publ)
STO:SOBI
|
Other
kr806m
|
CAGR 3-Years
N/A
|
CAGR 5-Years
41%
|
CAGR 10-Years
N/A
|
|
|
BioArctic AB
STO:BIOA B
|
Other
-kr1k
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
ExpreS2ion Biotech Holding AB
Glance View
Expres2ion Biotech Holding AB engages in the development of a portfolio of vaccines for diseases such as COVID-19, influenza, and breast cancer. The company is headquartered in Helsingborg, Skane and currently employs 29 full-time employees. The company went IPO on 2016-07-29. The firm specializes in developing cell lines and processes based on a non-viral Drosophila S2 cells expression system. The firm's ExpreS2 recombinant protein expression platform supports all phases of drug discovery, research and development and manufacturing. ExpreS2 is a non-viral insect cell expression system that establishes stable polyclonal pools that provide high-protein expression levels without selection pressure. The system is designed for transient or stable transfections using vector deoxyribonucleic acid containing a hybrid promoter. The company also ensures high cell density without aggregation or toxic metabolite build-up issues. Through the joint venture AdaptVac ApS, the Company applies a Plug-and-Play Virus Like Particle technology for development of therapeutic and prophylactic vaccines within oncology, infectious diseases and immunological disorders.
See Also
What is ExpreS2ion Biotech Holding AB's Other?
Other
-474k
SEK
Based on the financial report for Sep 30, 2025, ExpreS2ion Biotech Holding AB's Other amounts to -474k SEK.
What is ExpreS2ion Biotech Holding AB's Other growth rate?
Other CAGR 5Y
10%
Over the last year, the Other growth was 93%. The average annual Other growth rates for ExpreS2ion Biotech Holding AB have been 66% over the past three years , 10% over the past five years .
